Prestigious award for David Raulet
Innate Pharma raises euro 20 million in its second round of financing
Innate Pharma and Novo Nordisk A/S sign licensing deal
Innate Pharma strenghtens its management team with the recruitment of S.Boissel as CFO
Frank Morich joins Innate Pharma's board of Directors
Innate Pharma obtains ISO9001:2000 certification for its research and development activities in the field of immunotherapy
Innate Pharma announces the achievement of the first milestone in its collaboration with Novo Nordisk A/S
Innate Pharma welcomes Dr. Squiban as Chief Medical Officer
Calendrier financier pour 2008 et prochains RDV avec la communauté financière
IPH 2201, nouvel anticorps ciblant les cellules NK, entre en phase de développement pré-clinique réglementaire
